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Abstract Dihydropyrimidine dehydrogenase (DPD) is
the initial enzyme acting in the catabolism of the widely
used antineoplastic agent 5-ﬂuorouracil (5FU). DPD deﬁ-
ciency is known to cause a potentially lethal toxicity fol-
lowing administration of 5FU. Here, we report novel
genetic mechanisms underlying DPD deﬁciency in patients
presenting with grade III/IV 5FU-associated toxicity.
In one patient a genomic DPYD deletion of exons 21–23
was observed. In ﬁve patients a deep intronic muta-
tion c.1129–5923C[G was identiﬁed creating a cryptic
splice donor site. As a consequence, a 44 bp fragment
corresponding to nucleotides c.1129–5967 to c.1129–5924
of intron 10 was inserted in the mature DPD mRNA. The
deleterious c.1129–5923C[G mutation proved to be in cis
with three intronic polymorphisms (c.483 ? 18G[A,
c.959–51T[G, c.680 ? 139G[A) and the synonymous
mutation c.1236G[A of a previously identiﬁed haplotype.
Retrospective analysis of 203 cancer patients showed that
the c.1129–5923C[G mutation was signiﬁcantly enriched
in patients with severe 5FU-associated toxicity (9.1%)
compared to patients without toxicity (2.2%). In addition, a
high prevalence was observed for the c.1129–5923C[G
mutation in the normal Dutch (2.6%) and German (3.3%)
population. Our study demonstrates that a genomic deletion
affecting DPYD and a deep intronic mutation affecting
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DOI 10.1007/s00439-010-0879-3pre-mRNA splicing can cause severe 5FU-associated tox-
icity. We conclude that screening for DPD deﬁciency
should include a search for genomic rearrangements and
aberrant splicing.
Introduction
Dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2) is
the initial and rate-limiting enzyme in the catabolism of the
pyrimidine bases uracil and thymine but also of the anti-
neoplastic agent 5-ﬂuorouracil. The pivotal role of DPD in
5FU-based chemotherapy has been shown in cancer
patients with a complete or partial deﬁciency of this
enzyme. These patients suffered from severe, possibly fatal
multi-organ toxicity following the administration of 5FU
(Johnson and Diasio 2001; Milano et al. 1999; van Kuilen-
burg et al. 2000).
T h ep r e s e n c eo fm u t a t e dDPYD has been reported in
patients experiencing severe 5FU toxicity (Morel et al.
2006; van Kuilenburg et al. 2000). For that reason,
various strategies have been proposed to screen for
patients with a DPD deﬁciency, including genotyping
(Amstutz et al. 2009;K l e i b le ta l .2009). However, in a
signiﬁcant number of patients with a reduced DPD
activity, no mutations could be identiﬁed in the coding
part of DPYD (Collie-Duguid et al. 2000; Mattison et al.
2004; van Kuilenburg et al. 2000). The recent observa-
tion that a DPYD haplotype not containing any nonsyn-
onymous or splice-site mutations was associated with
5FU toxicity, suggested the presence of additional
genetic variations in the noncoding region of DPYD
(Amstutz et al. 2009). So far, no deep intronic mutations
in DPYD have been described affecting the splicing of
DPD pre-mRNA.
DPYD is present as a single copy gene on chromosome
1p21.3 and consists of 23 exons (Wei et al. 1998).
Recently, we showed that genomic deletions affecting
DPYD occurred in 7% of paediatric patients with a com-
plete DPD deﬁciency (van Kuilenburg et al. 2009).
Therefore, it is conceivable that genomic deletions
encompassing a part or the entire DPYD gene might also
provide a molecular basis for cancer patients with a phe-
notypically established DPD deﬁciency. In this study, we
investigated the presence or absence of genomic rear-
rangements in DPYD, using multiplex ligation-dependent
probe ampliﬁcation (MLPA), in 92 patients with a reduced
DPD activity and/or grade III/IV toxicity. Furthermore, we
characterized a novel missense mutation K874R based on
the crystal structure of DPD and identiﬁed the ﬁrst deep
intronic mutation in DPYD affecting the regulation of pre-
mRNA splicing.
Materials and methods
Patients
Ninety-two cancer patients with reduced DPD activity and/
or grade III/IV toxicity were examined for DPYD rear-
rangements. The study cohort consisted of 64 Dutch
patients who had been referred for diagnostic purposes
between 2007 and 2009 and proved to have a reduced DPD
activity in peripheral blood mononuclear cells (Milano
et al. 1999; van Kuilenburg et al. 2002b), ranging from
0.7–5.9 nmol/mg/h (local controls 9.6 ± 2.6 nmol/mg/h).
The DPD activity in 11 French cancer patients ranged from
0.7 to 10.6 nmol/mg/h (local controls 13.3 ± 5.0 nmol/
mg/min). In addition, 17 German patients presenting with
grade IV 5FU-associated toxicity were analysed, including
one previously reported patient (patient ‘‘2’’ from Gross
et al. 2003). Toxicity grading was based on the common
toxicity criteria and adverse event reporting guidelines
from the National Cancer Institute (NCI-CTC AE, version
3.0; http://ctep.cancer.gov/reporting/ctc.html). Four addi-
tional Dutch subjects of whom exonic sequence data were
available, including two patients with severe 5FU toxicity,
a son of a patient with lethal toxicity and a healthy vol-
unteer who was coincidently found to have a DPD deﬁ-
ciency during another study were further investigated for
intronic mutations and alternative splicing. Subsequently,
the presence of a deep intronic mutation was retrospec-
tively analysed in 66 German cancer patients presenting
with grade III/IV 5FU-associated toxicity and 137 patients
with no or mild toxicity (Supplemental Table 1). In addi-
tion, the prevalence of the mutation was investigated in 453
and 191 healthy individuals from Germany and the Neth-
erlands, respectively.
MLPA and array-based comparative genomic
hybridization analysis
Genomic DNA was isolated from EDTA-blood using
standard techniques. The MLPA test for DPYD (P103,
MRC-Holland, Amsterdam, The Netherlands) contains 38
probes for DPYD, including one probe to detect the
c.1905 ? 1G[A mutation, and nine control probes speciﬁc
for DNA sequences outside the DPYD gene. MLPA was
performed as described before (Schouten et al. 2002). Data
analysis was performed using Genescan and Genotyper
software (Applied Biosystems, Nieuwekerk a/d IJssel, The
Netherlands). The relative peak area of each probe was
divided by the average relative peak area of this probe in
control samples. In unaffected individuals this will result in
a value of 1 (100%) representing two copies of the target
sequence in the sample.
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123Array CGH was performed using commercially
available 105 K Agilent slides, AMADID 019015 with a
21.7 kB overall median probe spacing (Oxford design,
Agilent, Santa Clara, CA, USA) according to the
manufacturer’s protocol (Oligonucleotide Array-Based
CGH for Genomic DNA Analysis V5.0 June 2007).
Fluorescent labelling of DNA was performed using the
CGH labelling kit for Oligo Arrays (Enzo Life Sciences,
Inc., Farmingdale, NY, USA). Slides were scanned
using a 2 lm Agilent scanner, image analysis was per-
formed with Agilent Feature extraction V9.5.3 and data
analysis was performed using Agilent DNA Analytics
(V4.0.76).
Sequence analysis of cDNA and gDNA coding for DPD
DNA was isolated from blood using standard techniques.
PCR ampliﬁcation of all 23 coding exons and ﬂanking
intronic regions of DPYD was carried out using intronic
primer sets, essentially as described before (van Kuilenburg
et al. 2000). Exon 6 was ampliﬁed using the forward primer
DPYD6f (50-CTGAAAATGTACTGCTCATTGCT-30) and
reverse primer DPYD6r (50-GCTTCAAGCCAACTG
CAAAT-30). Part of intron 10 of DPYD was ampliﬁed using
the forward primer DPYD10f (50-TCAGACCAAATCAT
CGCATT-30) and reversed primer DPYD10r (50-TTC
TCCTCATGGCACCCATA-30).
Total RNA was isolated from 20 ml of heparinized
blood and cultured ﬁbroblasts using Trizol extraction
(Invitrogen, Carlsbad, CA, USA). cDNA was prepared
using a ﬁrst strand cDNA synthesis kit for RT-PCR
(Roche, Mannheim, Germany). PCR ampliﬁcation of a part
of the cDNA sequence of exons 8–11 was performed using
the forward primer (50-GCTACAAAGCTGCTTTCATTG-
30) and reverse primer (50-CACTGATGACCACATCGGC-
30), corresponding to the nucleotides c.824_844 (exon 8)
and c.1291_1309 (exon 11), respectively. cDNA analysis
of exon 22 was performed using the forward primer (50-
TGGACCTTATCTGGAACAGC-30) and reverse primer
(50-TCAGCATATGTAGGTGACATG-30) corresponding
to the nucleotides c.2637_2656 (exon 21) and c.3110_3130
(exon 23), respectively.
Ampliﬁcation of cDNA and part of intron 10 was carried
out in 25 ll reaction mixtures containing 20 mM Tris/HCl
pH 8.4, 50 mM KCl, 1.5 mM MgCl2, 0.4 lM of each
primer, 0.2 mM dNTPs and 0.02 U of Platinum Taq
polymerase. After initial denaturation for 5 min at 95C,
ampliﬁcation was carried out for 30 cycles (30 s 95C, 30 s
55C, 1 min 72C) with a ﬁnal extension step of 10 min at
72C. PCR products were separated on 1.5% agarose gels,
visualized with ethidium bromide or used for direct
sequencing.
Population screening for genomic DPYD mutations was
performed by direct sequence analysis and DHPLC, as pre-
viously described (Seck et al. 2005). Sequence analysis of
cDNAandgenomicfragmentsampliﬁedbyPCRwascarried
out on an Applied Biosystems model 3100 automated
DNA sequencer using the dye-terminator method (Applied
Biosystems, Nieuwekerk a/d IJssel, The Netherlands).
The DPYD sequence of patients was compared to that
observed in controls and in the reference sequence of DPYD
(Ref Seq NM_000110.3; Ensembl ENST00000370192).
Analysis of sequences for cryptic splice sites was performed
with Alamut 1.5 software (Interactive Biosoftware, Rouen,
France).
Quantitative PCR analysis
Quantitative PCR analysis of the wild-type DPD cDNA
and the cDNA containing the 44 bp insertion of intron 10
was performed using the forward primers 50-GAGGA
GATGGAGCTTGCTAA-30 and 50-AGGAGCATCAGC
CACATATC-30, respectively, and the reverse primer 50-C
TGAACCAAAGGCACTGATG-30. Quantitative PCR
analysis of the wild-type DPD cDNA and the cDNA con-
taining the exon 22 deletion was performed using the for-
ward primers 50-CCTACCATCAAGGATGTAAT-30 and
50-CCTACCATCAAGGCTATACA-30, respectively, and
the reverse primer 50-AGATAAGGGTACGCCTCTCT-30.
The analysis was performed using the LightCycler
 480
SYBR Green I Master kit (Roche Diagnostics Nederland
B.V, Almere, The Netherlands).
Crystal structure analysis
The homology model of human DPD was generated by
manual adjustment of the sequence of the deposited crystal
structure of recombinant pig DPD (PDB-ID: 1h7w;
Dobritzsch et al. 2001) to that of the human enzyme using
WinCoot (Emsley et al. 2010). An energetically preferred
side chain conformation was chosen that causes no steric
clashes with surrounding residues. The structural analysis
was performed using WinCoot. Figure 5 was generated
with the program PyMol (DeLano, W.L. The PyMOL
Molecular Graphics System (2002). http://www.pymol.org).
Statistics
Differences in the distribution of a variant or haplotype
between two groups were analysed by Pearson Chi-square
and the Mann–Whitney U test for independent samples.
Asymptotic signiﬁcance (two-sided) is indicated. Statistical
analysis was performed with the program PASW Statistics
18.
Hum Genet (2010) 128:529–538 531
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Analysis of intragenic rearrangements
MLPAanalysisshowedthepresenceofthec.1905 ? 1G[A
(IVS14 ? 1G[A) mutation in 28% (18/64) and 9% (1/11)
of cancer patients with a reduced DPD activity from the
Netherlands and France, respectively. One out of 17 (6%)
GermanpatientswithgradeIVtoxicityprovedtobeacarrier
for the c.1905 ? 1G[A mutation. Figure 1a shows the
MLPA analysis of the copy numbers of the 23 coding exons
and 4 intronic sequences of DPYD in the 92 cancer patients.
The mean variation observed for the various probes directed
against the exon and intron sequences of DPYD was
8.1 ± 1.8%, ranging from 5.0% for the exon 11.2 probe to
14.4%forthe exon1.1probe.Arelativecopy numberbelow
the cut-off value indicative for a deletion (relative copy
number \0.7) was observed for exons 1, 11 and 21–23
(Fig. 1a). A relatively large variation was observed for the
exon 1.1 probe and unfortunately, no DNA was available
anymore from this patient for further studies.
In patient 1, in whom sequence analysis of DPYD did
not provide unambiguous pathogenic mutations (patient 2
from Ref. Gross et al. 2003), MLPA analysis showed loss
of heterozygosity for exons 21–23 (Fig. 1b). Array-based
CGH was performed to delineate boundaries and size of the
deletion. Detailed analysis of the chromosome 1p21.3
region encompassing DPYD showed a minimal deleted
region of 61 kB ranging from 97320495 to 97381610,
encompassing exons 22 and 23, and a maximal deletion of
99 kB ranging from 97302551 to 97401528, encompassing
exons 21–23 of DPYD (Fig. 2).
In patient 2, MLPA analysis suggested a deletion of part
of exon 11 (Fig. 1c). However, sequence analysis of exon
11 and ﬂanking regions showed that the patient was
apparent homozygous for the c.1236G[A (p.E412E)
mutation which is located near the ligation site of the
MLPA probe 11.1. Therefore, the decreased signal is, most
likely, caused by a decreased hybridization or ligation of
the MLPA probe. Indeed, hybridization and ligation at a
lower temperature resulted in normalization of the signal
for the MLPA probe 11.1, thus excluding the presence of a
deletion (results not shown).
Identiﬁcation of a deep intronic mutation
affecting pre-mRNA splicing
Total RNA was isolated from EDTA-blood of patient 2 and
a control and subjected to RT-PCR ampliﬁcation. A part of
the coding sequence of the DPD cDNA, corresponding to
the nucleotides c.824_c.1309, was ampliﬁed and the PCR
fragments were analysed by gel electrophoresis. A normal
sized fragment of 486 bp was detected in a control subject
whereas the 486 bp fragment was found together with a
larger sized fragment of 530 bp in patient 2 (Fig. 3a).
Sequence analysis of the PCR fragments showed that the
530 bp fragment originated from the 486 bp fragment by
an insertion of 44 bp, corresponding to the nucleotides
c.1129–5967_c.1129–5924 of intron 10. Subsequent ana-
lysis of the corresponding sequence of intron 10 showed
that the patient was homozygous for a c.1129–5923C[G
mutation, creating a cryptic splice donor site (Fig. 3b). As a
consequence, a 44 bp fragment of intron 10 was inserted in
the mature DPD mRNA (Fig. 3b). The insertion leads to a
shifted reading frame, resulting in a premature stop codon
in exon 11.
Surprisingly,cDNAanalysisofpatient2alsorevealedthe
presence of an exon 22 deletion (c.[2767_2907del]) encod-
ing the amino acids 923–969 (Fig. 4). Quantitative PCR
showedthattheratioofthemutantDPDmRNAlackingexon
22 and wild-type DPD mRNA was 25 ± 3%. Sequence
analysisofexon22andﬂankingintronicsequencesofDPYD
of patient 2 did not reveal any mutations.
Retrospective analysis of our database with previously
analysed patients and controls revealed four additional
subjects (subjects 3–6) who were heterozygous for the
c.1236G[A (p.E412E) mutation (Table 1). Analysis of
intron 10 showed that these four subjects were heterozygous
for the c.1129–5923C[G mutation with the concomitant
insertion of nucleotides c.1129–5967_c.1129–5924 into the
DPD mRNA (Fig. 3). Thus, the c.1129–5923C[G mutation
and c.1236G[A (p.E412E) mutation are likely to be in cis.
Quantitative PCR showed that the ratio of the mutant DPD
mRNA, containing the 44 bp fragment of intron 10, and
wild-type DPD mRNA was 144 ± 6 and 28 ± 13% in
patient 2 and subject 3, respectively.
Analysis of the c.1236G[A and c.1129–5923C[G
mutation in 191 Dutch and 453 German healthy individuals
revealed a heterozygote frequency of 2.6 and 3.3%,
respectively. In 203 German patients who had been diag-
nosed for cancer between 2002 and 2009 and assessed for
5FU-associated side effects (Supplemental Table 1), we
retrospectively found nine cases carrying the c.1236G[A
and c.1129–5923C[G mutations. Six of them had experi-
enced severe grade III/IV 5FU-associated toxicity, mostly
neutropenia, leucopenia and diarrhoea. Overall, the dele-
terious allele was associated with 9.1% (6 of 66) of the
individuals with severe toxic effects compared to 2.2% (3
of 137) of the patients who tolerated the chemotherapy
regimen (P = 0.033).
Crystal structure analysis
Sequence analysis of the DPD gene of subject 3 also
revealed the presence of a novel missense mutation
c.2621A[G (p.K874R). Analysis of a three-dimensional
532 Hum Genet (2010) 128:529–538
123model of the human enzyme, based on the crystal structure
of the recombinant pig DPD, showed that the K874R site
belongs to a stretch of about 85 amino acids (856–941) that
connects the barrel domain IV with the ferredoxin-like core
of the C-terminal FeS-cluster domain V (Fig. 5). This
stretch is least conserved between DPDs from different
organisms and K874 itself is in mouse and rat DPD
replaced by a glutamine. The point mutation replaces the
long, ﬂexible and basic lysine side chain by a longer one of
equal charge (Fig. 5). Due to the location of the mutation
site on the protein surface, the orientation of the side chain
towards the solvent and the limited interaction with sur-
rounding residues, the effect of the amino acid exchange is
probably negligible.
Fig. 1 Analysis of copy
number changes in DPYD using
MLPA. a The box-plots of the
quantitative analysis of the copy
number of the 23 coding exons
and four intronic sequences of
DPYD and nine control probes
speciﬁc for DNA sequences
outside DPYD of 92 cancer
patients. The top, bottom and
line through the middle of a box
correspond to the 75th, 25th and
50th percentile, respectively.
The whiskers on the bottom
extend from the 2.5th percentile
and top 97.5th percentile. The
circles represent outliers. b The
MLPA analysis of patient 1
(ﬁlled square) and a control
(ﬁlled circle). c The MLPA
analysis of patient 2 (ﬁlled
square) and a control (ﬁlled
circle). The solid lines represent
the cut-off values indicative for
ampliﬁcation (relative copy
number[1.3) or deletion
(relative copy number\0.7) of
that particular sequence
Hum Genet (2010) 128:529–538 533
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5-Fluorouracil (5FU) and its oral prodrug capecitabine
(Xeloda
) are two of the most frequently prescribed che-
motherapeutic drugs for the adjuvant and palliative treat-
ment of patients with cancers of the gastrointestinal tract,
breast and head and neck (Meyerhardt and Mayer 2005;
Twelves et al. 2005). Although the beneﬁcial effects of
5FU and capecitabine are well established, the toxicity
associated with the treatment can be severe (Meyerhardt
and Mayer 2005). In this respect, it has been shown that a
DPD deﬁciency is an important pharmacogenetic syndrome
and the identiﬁcation of predictive genetic markers of
toxicity has become a challenging topic in the ﬁeld of
Fig. 2 Detection of copy
number changes by oligo array-
based genomic hybridization for
patient 1. The Y axis represents
the log2 ratio of the intensities
of patient and reference DNA.
On the X axis oligos are ordered
by Mb position. The lower
panel shows the observed log2
ratios on chromosome (Chr) 1.
The spikes outside the selected
area are known copy number
variants in the human DNA. The
upper panel shows a magniﬁed
view of the selected area in the
lower panel for the probes
located in DPYD and ﬂanking
regions. The genes located in
the ﬂanking region of DPYD are
indicated on the X axis. The
grey box represents the minimal
deleted region for patient 1
Fig. 3 PCR and sequence analysis of exon 11 and ﬂanking regions of
DPYD. a The PCR ampliﬁcation of a cDNA fragment using forward
and reverse primers located in exons 8 and 11, respectively. The 486
and 530 bp fragments correspond to the wild-type and mutated cDNA
fragments, respectively. MW marker: molecular weight marker;
1 control, 2 patient 3, 3 patient 2, 4 patient 4. b A schematic
representation of the region of intron 10 and the effect of the mutation
on splicing of the DPD pre-mRNA. The intronic sequence inserted
into the DPD mRNA is indicated in capital letters. The cryptic splice
acceptor and splice donor sites are indicated in italic
534 Hum Genet (2010) 128:529–538
123oncology (Amstutz et al. 2009; Gross et al. 2008; Morel
et al. 2006).
Analysis of the prevalence of the various DPYD muta-
tions, in cancer patients experiencing severe toxicity,
showed that the splice-site mutation c.1905 ? 1G[A
(IVS14 ? 1G[A) and the c.2846A[T (D949V) were the
most common pathological mutations (Loganayagam et al.
2010; Morel et al. 2006; Schwab et al. 2008; van Kuilen-
burg 2004). The high prevalence of c.1905 ? 1G[Am u t a -
tions in cancer patients with a reduced DPD activity from the
Netherlandsisinlinewithapreviousstudyintumourpatients
with severe 5FU toxicity (van Kuilenburg et al. 2002a).
Moreover, a relatively high incidence of the splice-site
mutation with 1.8% heterozygotes in the normal population
has been described (van Kuilenburg et al. 2001).
Previously, the analysis of 68 patients with high-grade
5FU-associated toxicity did not reveal large intragenic
rearrangements of DPYD (Ticha et al. 2009). In the present
study, unambiguous evidence for such a large genomic
deletion within DPYD was obtained in a patient with
reduced DPD activity and severe 5FU toxicity. The deleted
region, encompassing exons 21–23, was located outside the
common fragile site FRA1E which extends over 370 kb
within DPYD (Hormozian et al. 2007; van Kuilenburg et al.
Fig. 4 cDNA analysis of exon 22 and ﬂanking regions of DPYD of
patient 2. PCR ampliﬁcation of a cDNA fragment using forward and
reverse primers located in exons 21 and 23, respectively. The 494 and
353 bp fragments correspond to the wild-type and mutated cDNA
fragments, respectively
Table 1 DPD activity and DPD genotype in patients
gDNA cDNA Effect Patient 1
(F, 49)
a
Patient 2
(F, 50)
Subject 3
(F, 38)
Subject 4
(M, 50)
b
Subject 5
(M, 34)
c
Subject 6
(F, 62)
c.85T[C c.85T[C p.C29R ? ? ? ???
c.496A[G c.496A[G p.M166 V ?? ?
c.483 1 18G>A - ? ? ????
c.680 1 139G>A -? ? ? ? ? ? ? ?
c.959–51T>G - ? ? ????
c.1129–5923C[G c.1128_1129ins1129–5967_
1129–5924
Frameshift ? ? ????
c.1138–15T[C– ??
c.1236G>A c.1236G[A p.E412E ? ? ????
c.1601G[A c.1601G[A p.S534N ??
c.1627A[G c.1627A[G p.I534 V ??
c.1740 ? 39C[T -? ? ?
c.1740 ? 40A[G - ? ?? ?? ? ?? ?
c.1905 ? 1G[A c.1741_1905del p.581_635del ?
c.1974 ? 75A[G -?
c.2194G[A c.2194G[A p.V732I ?
c.2300–39G[A -? ?
c.2621A[G c.2621A[G p.K874R ?
Unknown c.2767_2907del p.923_969del ?
g.97302551_97401528del
d c.875_1025del Truncated protein ?
DPD activity (nmol/mg/h)
e 1.2 2.9 4.2 6.2 n.a. 1.6
Toxicity IV III III III
The mutations indicated in bold were part of a haplotype associated with severe 5FU toxicity (Amstutz et al. 2009)
n.a. not available
?, heterozygous; ??, homozygous
a Data taken from Gross et al. (2003)
b Healthy volunteer
c Son of a patient experiencing lethal toxicity
d Maximal deleted region
e DPD activity in peripheral blood mononuclear cells (control DPD activity was 9.6 ± 2.6 nmol/mg/h; van Kuilenburg et al. 2007)
Hum Genet (2010) 128:529–538 535
1232009). Common fragile sites represent chromosome struc-
tures that are particular prone to breakage under replication
stress and the genomic instability can give rise to deletions,
translocations and ampliﬁcations (Hormozian et al. 2007).
Recently, we showed the presence of large intragenic
rearrangements of DPYD and a de novo interstitial deletion
del(1)(p13.3p21.3)inﬁvepatientssufferingfromacomplete
DPD deﬁciency accompanied by a severe neurological
disorder (van Kuilenburg et al. 2009). The deletions
involving exons 12 and 14–16 were located within the
common fragile site FRA1E (Hormozian et al. 2007; van
Kuilenburg et al. 2009). The fact that a genomic deletion
affecting DPYD was observed in only 1 out of 92 patients
with reduced DPD activity and/or severe 5FU toxicity
indicates that rearrangements in DPYD are not a major
genetic cause underlying a partial DPD deﬁciency.
Recent advances in our understanding of pre-mRNA
splicing has led to an increased awareness that mutations
outside the splice sites may affect pre-mRNA splicing and
thereby causing disease (Pagani and Baralle 2004; Wang
and Cooper 2007). To date, alternative splicing of DPD
pre-mRNA has only been described for mutations in the
invariant splice donor sites of exons 11 and 14 (van
Kuilenburg et al. 2005; Vreken et al. 1996; Wei et al.
1996). Therefore, a conspicuous ﬁnding was a deep intro-
nic mutation affecting DPD pre-mRNA splicing in ﬁve
individuals. The c.1129–5923C[G mutation in intron 10
created a cryptic splice donor site and as a consequence, a
44 bp fragment of intron 10 was inserted in the mature
DPD mRNA. A systematic analysis of the sequences
present in the vicinity of the splice junctions has led to
consensus sequences for both the splice acceptor and splice
Fig. 5 Location and environment of the K874R mutation site in the
human DPD homology model. a Stereoview of the homodimeric DPD
in cartoon representation. One subunit is shown entirely in grey, the
domains of the other subunit are coloured as follows: FeS-cluster
domain I (amino acids 27–172), green; FAD-binding domain II
(173–286, 442–524), yellow; NADPH-binding domain III (287–441),
orange; FMN- and pyrimidine-binding domain IV (525–847),
salmon; FeS-cluster domain V (1–26, 848–1025), blue. Cofactors
are depicted as stick models in black for the coloured subunit, and in
grey for the other. The mutation site is indicated by a space-ﬁll model
of the native amino acid side chain, shown in red for one subunit only.
b Close-up stereoview of the K874R mutation site and its environ-
ment. The structure of the human DPD is shown in cartoon
representation and coloured according to a. Stick models of the iron
sulphur clusters are labelled according to Dobritzsch et al. (2001) and
shown with iron atoms in brown and sulphur atoms in yellow. The
stick-model of the native K874 is shown with carbon atoms in cyan,
that of the R874 side chain introduced by the mutation with carbon
atoms in magenta and thicker sticks. Residues surrounding the
mutation site (870–873, 875–876) are shown with thin sticks and
carbon atoms in cyan (colour ﬁgure online)
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123donor sites (Shapiro and Senapathy 1987). A scoring sys-
tem developed by Shapiro and Senapathy showed that
most naturally occurring splice acceptor and splice
donor sites yieldedscoresabove0.70.Analysisofthecryptic
splice acceptor and splice donor sites, created by the
c.1129–5923C[G mutation, showed consensus values of
0.87and0.90,respectively.However,the c.1129–5923C[G
mutation did not result in the exclusive generation of a
mutant transcript as the wild-type mRNA was found still to
be present in a patient apparent homozygous for the
c.1129–5923C[G mutation.
The c.1129–5923C[G mutation was presently detected
in all patients who were also a carrier of the c.1236G[A
(p.E412E) mutation and these two genetic mutations are
likely to be in cis. Genotype analysis of healthy individuals
showed that the frequency of heterozygosity for the
c.1236G[A mutation was 2.6, 3.3 and 1.9% in the Dutch,
German and Tunisian populations, respectively (Ben et al.
2007). In contrast, the mutation was not reported in 121
Korean and 341 Japanese individuals (Cho et al. 2007;
Maekawa et al. 2007). Conﬂicting data exist as to weather
the c.1236G[A mutation is associated with an increased
risk of development of severe 5FU-associated toxicity
(Kleibl et al. 2009; Schwab et al. 2008). However, a
haplotype containing three intronic polymorphisms
(c.483 ? 18G[A, c.959–51T[G, c.680 ? 139G[A) and
the c.1236G[A mutation was demonstrated to be associ-
ated with severe 5FU toxicity (Amstutz et al. 2009). In our
study, all patients who were a carrier of the
c.1129–5923C[G and c.1236G[A mutation, also pos-
sessed the three intronic mutations c.483 ? 18G[A,
c.959–51T[G and c.680 ? 139G[A. Thus, the increased
susceptibility for 5FU toxicity of carriers of this haplotype
is most likely due to the presence of the c.1129–5923C[G
mutation. This would be in line with our results which
showed that the c.1129–5923C[G mutation was signiﬁ-
cantly enriched in patients suffering from severe 5FU
toxicity.
Studies at the mRNA level are rarely performed and are
usually considered only when the effect of the mutation on
the encoded protein clearly does not explain the phenotype,
as in synonymous variations. The present study showed the
presence of a genomic deletion affecting DPYD and for the
ﬁrst time, a deep intronic mutation affecting DPD pre-
mRNA splicing. Therefore, screening of DPD deﬁcient
patients for genomic deletions and aberrant splicing should
be considered in case initial sequence analysis does not
reveal pathogenic mutations. In particular, the apparently
high prevalence of the c.1129–5923C[G mutation in the
normal population warrants genetic screening for this
mutation in cancer patients prior to the start of 5FU-con-
taining chemotherapy.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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